Rahul Banerjee, Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington, shared a post on X:
“IMS25 In my mind, this will be the slayer of ASCT more than any other MM regimen…
Excellent Tec-DVR and Tec-DR data [1x weekly Velcade and lots of IVIG in NDMM from MajesTEC-5. 100% ORR, 100% MRD neg across the board. This is what we hope for with induction!”
More posts featuring Rahul Banerjee on OncoDaily.
